160 related articles for article (PubMed ID: 7689973)
21. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
[TBL] [Abstract][Full Text] [Related]
22. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
[TBL] [Abstract][Full Text] [Related]
23. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
Hall H; Wedel I
Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
[TBL] [Abstract][Full Text] [Related]
24. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum.
Terai M; Hidaka K; Nakamura Y
Eur J Pharmacol; 1989 Dec; 173(2-3):177-82. PubMed ID: 2576228
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
Verhoeff NP; Bobeldijk M; Feenstra MG; Boer GJ; Maas MA; Erdtsieck-Ernste E; de Bruin K; van Royen EA
Int J Rad Appl Instrum B; 1991; 18(8):837-46. PubMed ID: 1839302
[TBL] [Abstract][Full Text] [Related]
26. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
[TBL] [Abstract][Full Text] [Related]
27. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study.
Amenta F; Bronzetti E; Felici L; Ricci A; Tayebati SK
J Auton Pharmacol; 1999 Jun; 19(3):151-9. PubMed ID: 10511471
[TBL] [Abstract][Full Text] [Related]
28. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors.
Tarazi FI; Yeghiayan SK; Baldessarini RJ; Kula NS; Neumeyer JL
Neuropsychopharmacology; 1997 Sep; 17(3):186-96. PubMed ID: 9272485
[TBL] [Abstract][Full Text] [Related]
29. [The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors].
Futamura T; Ohashi Y; Yano K; Takahashi Y; Haga K; Fukuda T
Nihon Yakurigaku Zasshi; 1996 May; 107(5):247-53. PubMed ID: 8690306
[TBL] [Abstract][Full Text] [Related]
30. Use of [3H]-clozapine as a ligand of the dopamine D4 receptor subtype in peripheral tissues.
Ricci A; Bronzetti E; Rossodivita I; Amenta F
J Auton Pharmacol; 1997 Aug; 17(4):261-7. PubMed ID: 9373785
[TBL] [Abstract][Full Text] [Related]
31. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1.
Primus RJ; Thurkauf A; Xu J; Yevich E; McInerney S; Shaw K; Tallman JF; Gallagher DW
J Pharmacol Exp Ther; 1997 Aug; 282(2):1020-7. PubMed ID: 9262371
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, in vitro binding profile and biodistribution of a 125I-labeled N-benzyl pyrrolidinyl benzamide derivative: a potential radioligand for mapping dopamine D2 receptors.
Saji H; Tanahashi K; Kinoshita T; Iida Y; Magata Y; Yokoyama A
Nucl Med Biol; 1996 Feb; 23(2):121-7. PubMed ID: 8868283
[TBL] [Abstract][Full Text] [Related]
33. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.
Tam SW; Cook L
Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5618-21. PubMed ID: 6147851
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J
Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161
[TBL] [Abstract][Full Text] [Related]
35. The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding.
Svartengren J; Celander M
Eur J Pharmacol; 1994 Mar; 254(1-2):73-81. PubMed ID: 7911431
[TBL] [Abstract][Full Text] [Related]
36. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
Wilmot CA; Szczepanik AM
Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
[TBL] [Abstract][Full Text] [Related]
37. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
Seeman P; Tallerico T
Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
[TBL] [Abstract][Full Text] [Related]
38. [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes.
Ujike H; Akiyama K; Kuroda S
Neuroreport; 1996 Apr; 7(5):1057-61. PubMed ID: 8804051
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization and autoradiographic localization of a putative dopamine D4 receptor in the heart.
Ricci A; Bronzetti E; Fedele F; Ferrante F; Zaccheo D; Amenta F
J Auton Pharmacol; 1998 Apr; 18(2):115-21. PubMed ID: 9730266
[TBL] [Abstract][Full Text] [Related]
40. Alteration of D1 and D2 dopaminergic receptor kinetics in specific rat brain regions following repeated administration of opiates.
Elwan MA; Soliman MR
Pharmacology; 1995 Aug; 51(2):73-83. PubMed ID: 8584575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
